Mobile

Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001013-18

Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin inhibitor (Sandimmun® Optoral or Prograf®) in stable renal transplant patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to show superiority of a CNI-free regimen with respect to renal function assessed by glomerular filtration rate (GFR) – Nankivell method – at Month 12 as compared to the standard CNI-based regimen in stable renal transplant patients.

Critère d'inclusion

  • maintenance kidney transplantation

Liens